Advances in nucleic acid delivery modalities now allow us to combine this understanding with the promiscuous nature of miRNAs to inhibit oncogenic networks.20 Revisiting classical oncogenic pathways, such as TGFβ signaling, with new mechanistic insights and tools can yield novel therapeutics to improve GBM patient outcomes. The gene discussed is TGFB1; the disease is glioblastoma.